ETFMG Treatments, Testing and Advancements ETF (GERM)

Delayed Data
As of Oct 23
 -0.06 / -0.21%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Treatments, Testing and Advancements Index. The fund invests at least 80% of its total assets in the component securities of the index. The index tracks the performance of U.S.-listed equity securities or depositary receipts of companies that (i) perform research, development, and commercialization of treatments or vaccines for infectious diseases or (ii) engage in the research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified.


1 month+5.88% 3 years--
3 months-12.70% 5 years--
1 year-- Since inception+14.18%
Data through 10/24/2020

Quote Details

Previous close$28.49
Open day’s range28.43 – 28.43
Net asset value (NAV)28.54 (10/23/2020)
Daily volume16,078
Average volume (3 months)1,537
Data as of 4:00pm ET, 10/23/2020

Peer Comparisonvs. Health ETFs

Performance 5-yr return--+10.93%
Expense Gross exp ratio0.68%1.22%
Risk 5 year sharpe ratio--0.59
Net assets$54.0M$3.5B
Average market cap$6.7B$40.5B
Average P/E--29.8
Dividend / Share--0.27%


No competitors data available.


Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
MRNA Moderna Inc6.48%
BNTX BioNTech SE5.97%
DGX Quest Diagnostics Inc5.47%
LH Laboratory Corporation of America Holdings5.47%
BIO Bio Rad Laboratories Inc5.41%
QDEL Quidel Corp5.08%
ADPT Adaptive Biotechnologies Corp4.37%
VIR Vir Biotechnology Inc4.27%
ALNY Alnylam Pharmaceuticals Inc4.21%
NVAX Novavax Inc4.08%